VTRS Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 12.68%. Viatris, Inc.'s return on equity of -21.75% beat Boston Scientific Corp.'s return on equity of 12.55%.

Viatris, Inc. has a consensus price target of $14.4444, signalling downside risk potential of -7.47%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 38.28%. Given that Boston Scientific Corp. has higher upside potential than Viatris, Inc., analysts believe Boston Scientific Corp. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.788, which suggesting that the stock is 21.162% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.15%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Viatris, Inc.'s net income of -$128.2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.28x versus 5.64x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 27.89%. Viatris, Inc.'s return on equity of -21.75% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Viatris, Inc. has a consensus price target of $14.4444, signalling downside risk potential of -7.47%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $609.82 which suggests that it could grow by 20.31%. Given that Intuitive Surgical, Inc. has higher upside potential than Viatris, Inc., analysts believe Intuitive Surgical, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.788, which suggesting that the stock is 21.162% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.15%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Viatris, Inc.'s net income of -$128.2M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 64.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.28x versus 18.27x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of -9.34%. Viatris, Inc.'s return on equity of -21.75% beat Pfizer Inc.'s return on equity of 10.84%.

Viatris, Inc. has a consensus price target of $14.4444, signalling downside risk potential of -7.47%. On the other hand Pfizer Inc. has an analysts' consensus of $28.43 which suggests that it could grow by 4.89%. Given that Pfizer Inc. has higher upside potential than Viatris, Inc., analysts believe Pfizer Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.788, which suggesting that the stock is 21.162% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.15%. Pfizer Inc. offers a yield of 6.35% to investors and pays a quarterly dividend of $0.43 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer Inc.'s is not.

Viatris, Inc. quarterly revenues are $3.8B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Viatris, Inc.'s net income of -$128.2M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.28x versus 2.47x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings, Inc. has a net margin of -3.41% compared to Viatris, Inc.'s net margin of 6.15%. Viatris, Inc.'s return on equity of -21.75% beat Zimmer Biomet Holdings, Inc.'s return on equity of 5.61%.

Viatris, Inc. has a consensus price target of $14.4444, signalling downside risk potential of -7.47%. On the other hand Zimmer Biomet Holdings, Inc. has an analysts' consensus of $102.65 which suggests that it could grow by 1.65%. Given that Zimmer Biomet Holdings, Inc. has higher upside potential than Viatris, Inc., analysts believe Zimmer Biomet Holdings, Inc. is more attractive than Viatris, Inc..

Viatris, Inc. has a beta of 0.788, which suggesting that the stock is 21.162% less volatile than S&P 500. In comparison Zimmer Biomet Holdings, Inc. has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.12%.

Viatris, Inc. has a quarterly dividend of $0.12 per share corresponding to a yield of 3.15%. Zimmer Biomet Holdings, Inc. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.24 per share. Viatris, Inc. pays 90.63% of its earnings as a dividend. Zimmer Biomet Holdings, Inc. pays out 27.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris, Inc. quarterly revenues are $3.8B, which are larger than Zimmer Biomet Holdings, Inc. quarterly revenues of $2.2B. Viatris, Inc.'s net income of -$128.2M is lower than Zimmer Biomet Holdings, Inc.'s net income of $137.9M. Notably, Viatris, Inc.'s price-to-earnings ratio is -- while Zimmer Biomet Holdings, Inc.'s PE ratio is 28.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris, Inc. is 1.28x versus 2.44x for Zimmer Biomet Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.